期刊文献+

无复流的药物处理 被引量:2

下载PDF
导出
摘要 无复流是指经皮冠状动脉介入治疗过程中,虽然已解除心外膜冠状动脉机械性梗阻,但血流仍持续减低或阻断,表现为造影剂排空延迟并伴有缺血症状。它是影响经皮冠状动脉介入治疗近期预后和远期心源性死亡及心脏事件的独立危险因素。目前,治疗无复流的药物有血小板糖蛋白Ⅱb/Ⅲa受体拮抗剂、腺苷、维拉帕米、硝普钠、尼可地尔、尼卡地平、肾上腺素等以期获得最大程度的心肌灌注,并改善预后。
出处 《国际心血管病杂志》 2007年第3期189-192,共4页 International Journal of Cardiovascular Disease
  • 相关文献

参考文献27

  • 1[1]Morishima I,Sone T,Oknmura K,at al.Angiographie noreflow phenomenon as a predictor of adverse long-term outcome in patients treated with percutaneous transluminal coronary angioplasty for first acute myocardial infarction[J].J Am Coll Cardiol,2000,36(4):1202-1209. 被引量:1
  • 2[2]Kawano H,Hayashida T,Ohtani H,et al.Histopathological findings of the no-reflow phenomenon following coronary intervention for acute coronary syndrome[J].Int Heart J,2005,46(2):327-332. 被引量:1
  • 3[3]Rubenstein MH,Finn AV,Leinbach RC,et al.Short-term intravenous eptifibatide infusion combined with reduced dose recombinant tissue plasminogen activator inhibits platelet recruitment at sites of coronary artery injury[J].J Am Coll Cardiol,2004,43(2):287-294. 被引量:1
  • 4[4]Bolognese L,Falsini G,Liistro F,et al.Randomized comparison of upstream tirofiban versus downstream high bolus dose tirofiban or abciximab on tissue-level perfusion and troponin release in high-risk acute coronary syndromes treated with percutaneous coronary interventions;the EVEREST trial[J].J Am Coll Cardiol,2006,47(3):522-528. 被引量:1
  • 5[5]Kastrati A,Mehilli J,Neumann FJ,et al.Abciximab in patients with acute coronary syndromes undergoing percutaneORS coronary intervention after clopidogrel pretreatment:the ISAR-REACT 2 randomized trial[J].JAMA,2006,295(13):1531-1538. 被引量:1
  • 6[6]Wohrle J,Grebe OC,Nusser T,et al.Reduction of major adverse cardiac events with intracoronary compared with intravenous bolus application of abciximab in patients with acute myocardial infarction or unstable angina undergoing coronary angioplasty[J].Circulation,2003,107(14):1840-1843. 被引量:1
  • 7[7]Naimushin YA,Mazurov AV.Role of glycoprotein Ⅱb-Ⅲa (alpha Ⅱb beta 3-integrin)in stimulation of secretion from platelet granules[J].Biochemistry (Mosc),2003,68(2):209-216. 被引量:1
  • 8[8]Baim DS,Wahr D,George B,et al.Randomized trial of a distal embolic protection device during percutaneous intervention of saphenous vein aorto-coronary bypass grafts[J].Circulation,2002,105(11):1285-1290. 被引量:1
  • 9[9]Werner GS,Lang K,Kuehnert H,et al.Intracoronary verapamil for reversal of no-reflow during coronary angioplasty for acute myocardial infarction[J].Catheter Cardiovasc Interv,2002,57(4):444-451. 被引量:1
  • 10[10]Assali AR,Sdringola S,Ghani M,et al.Intracoronary adenosine administered during percutaneous intervention in acute myocardial infarction and reduction in the incidence of "no reflow"phenomenon[J].Catheter Cardiovasc Interv,2000,51(1):27-31. 被引量:1

同被引文献7

引证文献2

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部